Progress toward Fulfilling the Potential of Immunomodulation in Childhood Neurodegeneration?

Mol Ther. 2017 Aug 2;25(8):1743-1745. doi: 10.1016/j.ymthe.2017.06.006. Epub 2017 Jun 16.

Authors

Jonathan D Cooper¹, Hemanth R Nelvagal²

Affiliations

¹ Department of Pediatrics, Los Angeles Biomedical Research Institute, David Geffen School of Medicine, UCLA, 1124 W Carson St., Torrance, CA 90502, USA. Electronic address: jonathan.cooper@labiomed.org.
² Department of Pediatrics, Los Angeles Biomedical Research Institute, David Geffen School of Medicine, UCLA, 1124 W Carson St., Torrance, CA 90502, USA.

No abstract available

Publication types

Comment

MeSH terms

Animals
Crotonates / pharmacology
Disease Models, Animal
Fingolimod Hydrochloride / pharmacology
Hydroxybutyrates
Immunomodulation*
Mice
Neurodegenerative Diseases
Neuronal Ceroid-Lipofuscinoses / drug therapy
Neuronal Ceroid-Lipofuscinoses / physiopathology*
Nitriles
Toluidines / pharmacology

Substances

Crotonates
Hydroxybutyrates
Nitriles
Toluidines
teriflunomide
Fingolimod Hydrochloride